Abstract 2820
Background
Fine-needle aspiration biopsy (FNAB) is the standard diagnostic method of thyroid nodules. However, a fraction of the cytology assessments generates indeterminate results. Our group developed a method based on the relative quantification of three transcripts to aid the diagnosis of thyroid lesions. In this study, we aimed to validate the performance and applicability of this diagnostic test in FNAB.
Methods
Seventy-five prospectively collected FNAB were evaluated for CLDN10, HMGA2 and LAMB3 gene expression (EIF2B1 as reference gene) by RT-qPCR, using the leftover cells inside the needles. A mathematical model previously established was applied and the scores were compared with the Bethesda categories and the final postoperative report.
Results
We demonstrated the feasibility of the molecular test, even with very small yields of RNA. The three genes tested showed higher expression in the conclusive malignant cases (15 Bethesda VI) in relation to the conclusive benign nodules (35 Bethesda II). The application of the diagnostic algorithm allowed the distinction of these samples with 93% sensitivity (14/15) and 100% specificity (35/35). Among the patient with indeterminate nodules (Bethesda III-V), the test was able to correctly discriminate malignant from benign nodules with 71% sensitivity (5/7 tumors) and 100% specificity (4/4 benign lesions). Fourteen indeterminate cases are being followed-up and were not submitted to surgery to date. Furthermore, we observed that larger tumors (>1 cm), presenting lymph node metastasis and extrathyroidal extension were associated with higher algorithm scores (total of 22 malignant cases).
Conclusions
A thyroid diagnostic method based on the analysis of only four genes by RT-qPCR (3 targets and 1 reference) revealed high accuracy and applicability even in very limited FNAB material, presenting also a potential prognostic role.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
FAPESP.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2376 - Patient Reported Outcomes (PRO) in patients (pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: A focus on subgroups with/ without visceral disease
Presenter: Johannes Ettl
Session: Poster Display session 2
Resources:
Abstract
4874 - Complete Responses in Patients With 2nd-Line or Greater Metastatic Triple-Negative Breast Cancer (TNBC) Following First-in-Human Immunotherapy Combining NK and T Cell Activation with Off-the-Shelf High-Affinity CD16 NK Cell Line (haNK)
Presenter: Chaitali Nangia
Session: Poster Display session 2
Resources:
Abstract
4362 - Reproducibility and concordance of 4 clinically developed programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) assays in triple-negative breast cancer (TNBC)
Presenter: Aurelia Noske
Session: Poster Display session 2
Resources:
Abstract
4528 - Systemic Therapy in 2nd-Line Metastatic Triple Negative Breast Cancer (mTNBC): A Systematic Literature Review (SLR) and Meta-Analysis (MA) of Efficacy
Presenter: Peter Kaufman
Session: Poster Display session 2
Resources:
Abstract
4112 - Cisplatin given at three divided doses for three consecutive days in metastatic breast cancer: an alternative schedule for one full dose with comparable efficacy but less CINV and hypomagnesaemia
Presenter: Yang Chen
Session: Poster Display session 2
Resources:
Abstract
5699 - Patterns and predictors of first-line (1L) taxane use in US patients with metastatic triple-negative breast cancer (mTNBC)
Presenter: Joyce O’Shaughnessy
Session: Poster Display session 2
Resources:
Abstract
1931 - Maintenance Chemotherapy is effective in Patients with Metastatic Triple Negative Breast Cancer After First-line Platinum-based Chemotherapy
Presenter: Jian Zhang
Session: Poster Display session 2
Resources:
Abstract
4696 - Using the Patient-Reported Outcomes Measurement Information System (PROMIS) to investigate symptom burden enrichment in Stage IV patients at an academic center
Presenter: Madeline Matthys
Session: Poster Display session 2
Resources:
Abstract
4582 - Measures of functional status in adults aged ≥70 years with advanced breast cancer (ABC) receiving palbociclib (PAL) combination therapy in POLARIS
Presenter: Meghan Karuturi
Session: Poster Display session 2
Resources:
Abstract
3565 - Real-World 1-Year Survival Analysis of Patients with Metastatic Breast Cancer with Liver or Lung Metastasis Treated with Eribulin, Gemcitabine or Capecitabine
Presenter: Shayma Kazmi
Session: Poster Display session 2
Resources:
Abstract